Ecto- and cytosolic 5′-nucleotidases in normal and AMP deaminase-deficient human skeletal muscle

Biological Chemistry

Volumn 387, Issue 1, 2006, Pages 53-58

  Hanisch, Frank ^a   Hellsten, Ylva ^b   Zierz, Stephan ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adenosine monophosphate (AMP) deaminase; AMPD1 gene; Cytosolic AMP 5 nucleotidase; Ecto 5 nucleotidase

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE PHOSPHATE; ECTO 5' NUCLEOTIDASE;

ARTICLE; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENOTYPE; HUMAN; HUMAN TISSUE; MUSCLE BIOPSY; MUSCLE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; WESTERN BLOTTING;

5'-NUCLEOTIDASE; ADOLESCENT; ADULT; AGED; AMP DEAMINASE; CYTOSOL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUTATION; PATIENTS;

EID: 30644479831     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2006.008     Document Type: Article

References (39)

1. Anderson, J.L. (2004). A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J. Card. Fail. 10, 316-320.
2. Anderson, J.L., Habashi, J., Carlquist, J.R, Muhlestein, J.B., Horne, B.D., Bair, T.L., Pearson, R.R., and Hart, N. (2000). A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J. Am. Coll. Cardiol. 36, 1248-1252.
3. Arabadjis, P.G., Tullson P.C., and Terjung, R.L. (1993). Purine nucleoside formation in rat skeletal muscle fiber types. Am. J. Physiol. 264, C1246-1251.
4. Bookman, E.L. and McKenzie, J.E. (1993). Tissue adenosine content in active soleus and gracilis muscles of cats. Am. J. Physiol. 244, H552-559.
5. Camici, M., Fini, C., and Ipata, P.L. (1985). Isolation and kinetic properties of 5′-nucleotidase from guinea-pig skeletal muscle. Biochim. Biophys. Acta 840, 6-12.
6. Cheng, B., Essackjee, H.C., and Ballard, H.J. (2000). Evidence for control of adenosine metabolism in rat oxidative skeletal muscle by changes in pH. J. Physiol. 522, 467-477.
7. Crowther, G.J., Carey, M.F., Kemper, W.F., and Conley, K.E. (2002). Control of glycolysis in contracting skeletal muscle. I. Turning it on. Am. J. Physiol. Endocrinol. Metab. 282, E67-E73.
8. Fishbein, W.N., Griffin, J.L., and Armbrustmacher, V.W. (1980). Stain for skeletal muscle adenylate deaminase. An effective tetrazolium stain for frozen biopsy specimens. Arch. Pathol. Lab. Med. 104, 462-466.
9. Gastmann, A, Sigusch, H.H., Henke, A., Reinhardt, D., Surber, R., Gastmann, O., and Figulla, H.R. (2004). Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure: influence on tumor necrosis factor-α level and outcome. Am. J. Cardiol. 93, 1260-1264.
10. Gross, M. (1997). Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency. J. Inherit. Metab. Dis. 20, 186-192.
11. Gross, M., Rotzer, E., Kolle, P., Mortier, W., Reichmann, H., Goebel, H.H., Lochmüller, H., Pongratz, D., Mahnke-Zizelman, D.K., and Sabina, R.L. (2002). A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population. Neuromuscul. Disord. 12, 558-565.
12. Hellsten, Y. (1999). The effect of muscle contraction on the regulation of adenosine formation in rat skeletal muscle cells. J. Physiol. 518, 761-768.
13. Hellsten, Y., Maclean, D., Rådegran, G., Saltin, B., and Bangsbo, J. (1998). Adenosine concentrations in the interstitium of resting and contracting human skeletal muscle. Circulation 98, 6-8.
14. Hellsten, Y., Richter, E.A., Kiens, B., and Bangsbo, J. (1999). AMP deamination and purine exchange in human skeletal muscle during and after intense exercise. J. Physiol. 520, 909-920.
15. Hunsucker, S.A., Spychala, J., and Mitchell, B.S. (2001). Human cytosolic 5′-nucleotidase I: characterization and role in nucleotide analog resistance. J. Biol. Chem. 276, 10498-10504.
16. Itoh, R. and Yamada, K. (1991). Determination of cytoplasmic 5′-nucleotidase which preferentially hydrolyses 6-hydroxypurine nucleotides in pig, rat and human tissues by immunotitration. Int. J. Biochem. 23, 461-465.
17. Itoh, R., Echizen, H., Higuchi, M., Oka, J., and Yamada, K. (1992). A comparative study on tissue distribution and metabolic adaptation of IMP-GMP 5′-nucleotidase. Comp. Biochem. Physiol. B 103, 153-159.
18. Kalsi, K.K., Yuen, A.H., Rybakowska, I.M., Johnson, P.H., Slominska, E., Birks, K. Kaletha, K., Yacoub, M.H., and Smolenski, R.T. (2003). Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation - a potential mechanism for protection in heart failure. Cardiovasc. Res. 59, 678-684.
19. Loh, E., Rebbeck, T.R., Mahoney, P.D., DeNofrio, D., Swain, J.L., and Holmes, E.W. (1999). Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 99, 1422-1425.
20. Lynge, J., Juel, C., and Hellsten, Y. (2001). Extracellular formation and uptake of adenosine during skeletal muscle contraction in the rat: role of adenosine transporters. J. Physiol. 537, 597-605.
21. Morisaki, T., Gross, M., Morisaki, H., Pongratz, D., Zöllner, N., and Holmes, E.W. (1992). Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc. Natl. Acad. Sci. USA 89, 6457-6461.
22. Newby, A.C., Luzio, J.P., and Hales, C.N. (1975). The properties and extracellular location of 5′ nucleotidase of the rat fat-cell plasma membrane. Biochem. J. 146, 625-633.
23. Norman, B., Mahnke-Zizelman, D.K., Vallis, A., and Sabina, R.L. (1998). Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle. J. Appl. Physiol. 85, 1273-1278.
24. Norman, B., Sabina, R.L., and Jansson, E. (2001). Regulation of skeletal muscle ATP catabolism by AMPD1 genotype during sprint exercise in asymptomatic subjects. J. Appl. Physiol. 91, 258-264.
25. Rådegran, G. and Hellsten, Y. (2000). Adenosine and nitric oxide in exercise-induced human skeletal muscle vasodilatation. Acta Physiol. Scand. 168, 575-591.
26. Rubio, J.C., Martin, M.A., Del Hoyo, P., Bautista, J., Campos, Y., Segura, D., Navarro, C., Ricoy, J.R., Cabello, A., and Arenas, J. (2000). Molecular analysis of Spanish patients with AMP deaminase deficiency. Muscle Nerve 23, 1175-1178.
27. Rohnd, J.M., Matthews, Y., and Jones, D.A. (1980). A quick simple and reliable method for ATPase in human muscle preparations. Histochem. J. 12, 707-709.
28. Rundell, K.W., Tullson, P.C., and Terjung, R.L. (1992). Altered kinetics of AMP deaminase by myosin binding. Am. J. Physiol. 263, C294-299.
29. Sabina, R.L., Swain, J.L., Olanow, C.W., Bradley, W.G., Fishbein, W.N., DiMauro, S., and Holmes, H.W. (1984). Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J. Clin. Invest. 73, 720-730.
30. Sabina, R.L., Morisaki, T., Clarke, R, Eddy, R., Shows, T.B., Morton, C.C., and Holmes, W. (1990). Characterization of the human and rat myoadenylate deaminase genes. J. Biol. Chem. 265, 9423-9433.
31. Sabina, R.L., Fishbein, W.N., Pezeshkpour, G., Clarke, P.R., and Holmes, E.W. (1992). Molecular analysis of the myoadenylate deaminase deficiencies. Neurology 42, 170-179.
32. Tarnopolsky, M.A., Parise, G., Gibala, M.J., Graham, T.E., and Rush, J.W.E. (2001). Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J. Physiol. 533, 881-889.
33. Tullson, P.C. and Terjung, R.L. (1991). Adenosine nucleotide metabolism in contracting skeletal muscle. Exer. Sport Sci. Rev. 14, 507-536.
34. Tullson, P.C. and Terjung, R.L. (1999). IMP degradative capacity in rat skeletal muscle fiber types. Mol. Cell. Biochem. 199, 111-117.
35. Tullson, P.C., Whitlock, D.M., and Terjung, R.L. (1990). Adenine nucleotide degradation in slow-twitch red muscle. Am. J. Physiol. 258, C258-265.
36. Verzijl, H.T., van Engelen, B.G., Luyten, J.A., Steenbergen, G.C., van den Heuvel, L.P., ter Laak, H.J., Padberg, G.W., and Wevers, R.A. (1998). Genetic characterization of myoadenylate deaminase deficiency. Ann. Neurol. 44, 140-143.
37. Yazaki, Y., Muhlestein, J.B., Carlquist, J.F., Bair, T.L., Horne, B.D., Renlund, D.G., and Anderson, J.L. (2004). A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J. Card. Fail. 10, 316-320.
38. Zimmermann, H. (2000). Extracellular metabolism of ATP and other nucleotides. Naunyn-Schmiedeberg's Arch. Pharmacol. 362, 299-309.
39. Zöllner, N., Reiter, S., and Gross, M. (1986). Myoadenylate deaminase deficiency: successful symptomatic therapy by high dose oral administration of ribose. Klin. Wochenschr. 64, 1281-1290.